-
1
-
-
84904543855
-
Anti-inflammatory therapies for cardiovascular disease
-
Ridker, P. M. & Luscher, T. F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782-1791 (2014).
-
(2014)
Eur. Heart J.
, vol.35
, pp. 1782-1791
-
-
Ridker, P.M.1
Luscher, T.F.2
-
2
-
-
85027200588
-
Mirroring the CANTOS revolution: Is anti-inflammatory therapy for diabetes just around the corner?
-
Tenenbaum, A. & Fisman, E. Z. Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner? Cardiovasc. Diabetol. 16, 91 (2017).
-
(2017)
Cardiovasc. Diabetol.
, vol.16
, pp. 91
-
-
Tenenbaum, A.1
Fisman, E.Z.2
-
3
-
-
77957280402
-
Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS
-
Makó, V. et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A. 77, 962-970 (2010).
-
(2010)
Cytometry A.
, vol.77
, pp. 962-970
-
-
Makó, V.1
-
4
-
-
84863700565
-
Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation
-
Salt, I. P. & Palmer, T. M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin. Investig. Drugs. 21, 1155-1167 (2012).
-
(2012)
Expert Opin. Investig. Drugs.
, vol.21
, pp. 1155-1167
-
-
Salt, I.P.1
Palmer, T.M.2
-
5
-
-
84901807090
-
The TLR and IL-1 signalling network at a glance
-
Cohen, P. The TLR and IL-1 signalling network at a glance. J. Cell. Sci. 127, 2383-2390 (2014).
-
(2014)
J. Cell. Sci.
, vol.127
, pp. 2383-2390
-
-
Cohen, P.1
-
6
-
-
84856297871
-
Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
-
Davies, C. & Tournier, C. Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem. Soc. Trans. 40, 85-89 (2012).
-
(2012)
Biochem. Soc. Trans.
, vol.40
, pp. 85-89
-
-
Davies, C.1
Tournier, C.2
-
7
-
-
85019072998
-
Sodium glucose co-transporters and their inhibition: Clinical physiology
-
Ferrannini, E. Sodium glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27-38 (2017).
-
(2017)
Cell Metab.
, vol.26
, pp. 27-38
-
-
Ferrannini, E.1
-
8
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
-
9
-
-
85023777061
-
CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal, B. et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644-657 (2017).
-
(2017)
N. Engl. J. Med.
, vol.377
, pp. 644-657
-
-
Neal, B.1
-
10
-
-
84964773926
-
SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study
-
Abdul-Ghani, M., Del Prato, S., Chilton, R. & DeFronzo, R. A. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 39, 717-725 (2016).
-
(2016)
Diabetes Care.
, vol.39
, pp. 717-725
-
-
Abdul-Ghani, M.1
Del Prato, S.2
Chilton, R.3
DeFronzo, R.A.4
-
11
-
-
84964507777
-
SGLT2 inhibition and cardiovascular events: Why did EMPAREG outcomes surprise and what were the likely mechanisms?
-
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D. & McMurray, J. J. SGLT2 inhibition and cardiovascular events: why did EMPAREG outcomes surprise and what were the likely mechanisms? Diabetologia 59, 1333-1339 (2016).
-
(2016)
Diabetologia
, vol.59
, pp. 1333-1339
-
-
Sattar, N.1
McLaren, J.2
Kristensen, S.L.3
Preiss, D.4
McMurray, J.J.5
-
12
-
-
84975853831
-
CV protection in the EMPA-REG OUTCOME trial: A "thrifty substrate" hypothesis
-
Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care. 39, 1108-1114 (2016).
-
(2016)
Diabetes Care.
, vol.39
, pp. 1108-1114
-
-
Ferrannini, E.1
Mark, M.2
Mayoux, E.3
-
13
-
-
85026920030
-
The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipidmetabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice
-
Nakatsu, Y. et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipidmetabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int. J. Mol. Sci. 18, 1704 (2017).
-
(2017)
Int. J. Mol. Sci.
, vol.18
, pp. 1704
-
-
Nakatsu, Y.1
-
14
-
-
84995768100
-
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
-
Han, J. H. et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia 60, 364-376 (2017).
-
(2017)
Diabetologia
, vol.60
, pp. 364-376
-
-
Han, J.H.1
-
15
-
-
84911942671
-
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
-
Oelze, M. et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 9, e112394 (2014).
-
(2014)
PLoS One.
, vol.9
, pp. e112394
-
-
Oelze, M.1
-
16
-
-
85017220425
-
Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse
-
Salim, H. M. et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front. Cardiovasc. Med. 3, 43 (2016).
-
(2016)
Front. Cardiovasc. Med.
, vol.3
, pp. 43
-
-
Salim, H.M.1
-
17
-
-
85021409196
-
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
-
Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370-385 (2017).
-
(2017)
Redox Biol.
, vol.13
, pp. 370-385
-
-
Steven, S.1
-
18
-
-
84946434020
-
SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
-
Han, Y. et al. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1027-1036 (2015).
-
(2015)
Am. J. Physiol. Lung Cell. Mol. Physiol.
, vol.309
, pp. L1027-L1036
-
-
Han, Y.1
-
19
-
-
84987624200
-
The Na +/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels
-
Hawley, S. A. et al. The Na +/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65, 2784-2794 (2016).
-
(2016)
Diabetes
, vol.65
, pp. 2784-2794
-
-
Hawley, S.A.1
-
20
-
-
84992195114
-
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
-
Villani, L. A. et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol. Metab. 5, 1048-1056 (2016).
-
(2016)
Mol. Metab.
, vol.5
, pp. 1048-1056
-
-
Villani, L.A.1
-
21
-
-
85020822242
-
AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance
-
Garcia, D. & Shaw, R. J. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol. Cell. 66, 789-800 (2017).
-
(2017)
Mol. Cell.
, vol.66
, pp. 789-800
-
-
Garcia, D.1
Shaw, R.J.2
-
22
-
-
85019662904
-
AMP-activated protein kinase: An ubiquitous signaling pathway with key roles in the cardiovascular system
-
Salt, I. P. & Hardie, D. G. AMP-activated protein kinase: an ubiquitous signaling pathway with key roles in the cardiovascular system. Circ. Res. 120, 1825-1841 (2017).
-
(2017)
Circ. Res.
, vol.120
, pp. 1825-1841
-
-
Salt, I.P.1
Hardie, D.G.2
-
23
-
-
85018253813
-
SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
-
Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119-132 (2017).
-
(2017)
Cardiovasc. Drugs Ther.
, vol.31
, pp. 119-132
-
-
Ye, Y.1
Bajaj, M.2
Yang, H.C.3
Perez-Polo, J.R.4
Birnbaum, Y.5
-
24
-
-
14344257169
-
AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells
-
Cacicedo, J. M. et al. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 324, 1204-1209 (2004).
-
(2004)
Biochem. Biophys. Res. Commun.
, vol.324
, pp. 1204-1209
-
-
Cacicedo, J.M.1
-
25
-
-
79958078455
-
Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells
-
Bess, E., Fisslthaler, B., Frömel, T. & Fleming, I. Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells. PLoS One. 6, e20848 (2011).
-
(2011)
PLoS One.
, vol.6
, pp. e20848
-
-
Bess, E.1
Fisslthaler, B.2
Frömel, T.3
Fleming, I.4
-
26
-
-
57549088860
-
Inhibition of tumour necrosis factor-alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase
-
Ewart, M. A., Kohlhaas, C. F. & Salt, I. P. Inhibition of tumour necrosis factor-alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 28, 2255-2257 (2008).
-
(2008)
Arterioscler. Thromb. Vasc. Biol.
, vol.28
, pp. 2255-2257
-
-
Ewart, M.A.1
Kohlhaas, C.F.2
Salt, I.P.3
-
27
-
-
84996807783
-
Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation
-
Mancini, S. J. et al. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol. Cell. Endocrinol. 440, 44-56 (2017).
-
(2017)
Mol. Cell. Endocrinol.
, vol.440
, pp. 44-56
-
-
Mancini, S.J.1
-
28
-
-
84942506312
-
Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor
-
Devineni, D. & Polidori, D. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 54, 1027-1041 (2015).
-
(2015)
Clin. Pharmacokinet.
, vol.54
, pp. 1027-1041
-
-
Devineni, D.1
Polidori, D.2
-
29
-
-
79951897566
-
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
-
Kasichayanula, S. et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes. Metab. 13, 357-365 (2011).
-
(2011)
Diabetes Obes. Metab.
, vol.13
, pp. 357-365
-
-
Kasichayanula, S.1
-
30
-
-
84872111344
-
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
-
Brand, T., Macha, S., Mattheus, M., Pinnetti, S. & Woerle, H. J. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv. Ther. 29, 889-899 (2012).
-
(2012)
Adv. Ther.
, vol.29
, pp. 889-899
-
-
Brand, T.1
Macha, S.2
Mattheus, M.3
Pinnetti, S.4
Woerle, H.J.5
-
31
-
-
84896826460
-
Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
-
Scheen, A. J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53, 213-225 (2014).
-
(2014)
Clin. Pharmacokinet.
, vol.53
, pp. 213-225
-
-
Scheen, A.J.1
-
32
-
-
0033815967
-
Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase
-
Woods, A. et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell. Biol. 20, 6704-6711 (2000).
-
(2000)
Mol. Cell. Biol.
, vol.20
, pp. 6704-6711
-
-
Woods, A.1
-
33
-
-
45549088112
-
Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase
-
Boyle, J. G. et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem. 283, 11210-11217 (2008).
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 11210-11217
-
-
Boyle, J.G.1
-
34
-
-
84890963021
-
Structural basis of AMPK regulation by small molecule activators
-
Xiao, B. et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 4, 3017 (2013).
-
(2013)
Nat. Commun.
, vol.4
, pp. 3017
-
-
Xiao, B.1
-
35
-
-
0030071339
-
MTS interferon assay: A simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt
-
Khabar, K. S. et al. MTS interferon assay: a simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt. J. Interferon Cytokine Res. 16, 31-33 (1996).
-
(1996)
J. Interferon Cytokine Res.
, vol.16
, pp. 31-33
-
-
Khabar, K.S.1
-
36
-
-
85006515958
-
Transendothelial glucose transport is not restricted by extracellular hyperglycaemia
-
Tumova, S., Kerimi, A., Porter, K. E. & Williamson, G. Transendothelial glucose transport is not restricted by extracellular hyperglycaemia. Vascul. Pharmacol. 87, 219-229 (2016).
-
(2016)
Vascul. Pharmacol.
, vol.87
, pp. 219-229
-
-
Tumova, S.1
Kerimi, A.2
Porter, K.E.3
Williamson, G.4
-
37
-
-
84885852033
-
Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway
-
Chen, M. L. et al. Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway. J. Nutr. Biochem. 24, 1823-1829 (2013).
-
(2013)
J. Nutr. Biochem.
, vol.24
, pp. 1823-1829
-
-
Chen, M.L.1
-
38
-
-
84857099986
-
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
-
Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7, e30555 (2012).
-
(2012)
PLoS One
, vol.7
, pp. e30555
-
-
Liang, Y.1
-
39
-
-
85019618220
-
The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model
-
Joubert, M. et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66, 1030-1040 (2017).
-
(2017)
Diabetes
, vol.66
, pp. 1030-1040
-
-
Joubert, M.1
-
40
-
-
36549040859
-
The selectivity of protein kinase inhibitors: A further update
-
Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
-
(2007)
Biochem. J.
, vol.408
, pp. 297-315
-
-
Bain, J.1
-
41
-
-
85047689953
-
5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?
-
Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565 (1995).
-
(1995)
Eur. J. Biochem.
, vol.229
, pp. 558-565
-
-
Corton, J.M.1
Gillespie, J.G.2
Hawley, S.A.3
Hardie, D.G.4
-
42
-
-
84857926956
-
Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification
-
Pinter, K., Jefferson, A., Czibik, G., Watkins, H. & Redwood, C. Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification. Cell Cycle 11, 917-921 (2012).
-
(2012)
Cell Cycle
, vol.11
, pp. 917-921
-
-
Pinter, K.1
Jefferson, A.2
Czibik, G.3
Watkins, H.4
Redwood, C.5
-
43
-
-
81755174323
-
AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300
-
Zhang, Y., Qiu, J., Wang, X. & Xia, M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. 31, 2897-2908 (2011).
-
(2011)
Arterioscler. Thromb. Vasc. Biol.
, vol.31
, pp. 2897-2908
-
-
Zhang, Y.1
Qiu, J.2
Wang, X.3
Xia, M.4
-
44
-
-
34247340098
-
MTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells
-
Schreml, S., Lehle, K., Birnbaum, D. E. & Preuner, J. G. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int. Immunopharmacol. 7, 781-790 (2007).
-
(2007)
Int. Immunopharmacol.
, vol.7
, pp. 781-790
-
-
Schreml, S.1
Lehle, K.2
Birnbaum, D.E.3
Preuner, J.G.4
-
45
-
-
84875873193
-
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
-
Wang, C. et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J. Clin. Invest. 123, 1677-1693 (2013).
-
(2013)
J. Clin. Invest.
, vol.123
, pp. 1677-1693
-
-
Wang, C.1
-
46
-
-
84880057785
-
AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells
-
Takeuchi, K. et al. AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells. J. Biol. Chem. 288, 20581-20591 (2013).
-
(2013)
J. Biol. Chem.
, vol.288
, pp. 20581-20591
-
-
Takeuchi, K.1
-
47
-
-
84994908860
-
Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling
-
Rutherford, C. et al. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci. Signal. 9, ra109 (2016).
-
(2016)
Sci. Signal.
, vol.9
, pp. ra109
-
-
Rutherford, C.1
-
48
-
-
84997354438
-
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
-
Naznin, F. et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 794, 37-44 (2017).
-
(2017)
Eur. J. Pharmacol.
, vol.794
, pp. 37-44
-
-
Naznin, F.1
-
49
-
-
0030592623
-
The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro
-
Woods, A., Salt, I., Scott, J., Hardie, D. G. & Carling, D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397, 347-351 (1996).
-
(1996)
FEBS Lett.
, vol.397
, pp. 347-351
-
-
Woods, A.1
Salt, I.2
Scott, J.3
Hardie, D.G.4
Carling, D.5
-
50
-
-
85009460365
-
Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487
-
Heathcote, H. R. et al. Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487. Biochem. J. 473, 4681-4697 (2016).
-
(2016)
Biochem. J.
, vol.473
, pp. 4681-4697
-
-
Heathcote, H.R.1
|